SMS Pharma.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE812G01025
  • NSEID: SMSPHARMA
  • BSEID: 532815
INR
320.00
4 (1.27%)
BSENSE

Feb 09

BSE+NSE Vol: 5.97 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationNine Monthly Results
Results Snapshot
Figures in Cr
Consolidate Nine Monthly Results
Dec'25
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
Net Sales
648.93
534.55
463.46
372.62
458.95
391.89
315.48
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
648.93
534.55
463.46
372.62
458.95
391.89
315.48
Raw Material Cost
392.41
384.33
327.80
224.35
347.73
226.71
198.05
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
-27.85
-95.18
-64.22
24.98
-105.38
17.93
-10.63
Employee Cost
58.49
53.45
42.21
39.26
37.23
28.80
29.14
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
67.26
60.94
51.54
40.60
43.80
27.99
24.94
Selling and Distribution Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Expenses
27.24
32.82
23.13
12.17
17.29
10.45
8.33
Total Expenditure (Excl Depreciation)
517.55
436.36
380.46
341.36
340.67
311.88
249.83
Operating Profit (PBDIT) excl Other Income
131.38
98.19
83.00
31.26
118.28
80.01
65.65
Other Income
5.78
4.80
2.81
3.62
4.77
2.17
2.02
Operating Profit (PBDIT)
137.16
102.99
85.81
34.88
123.05
82.18
67.67
Interest
17.80
13.47
17.84
16.03
14.53
8.61
9.34
Exceptional Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Gross Profit (PBDT)
119.36
89.52
67.97
18.85
108.52
73.57
58.33
Depreciation
29.79
25.70
23.60
24.15
24.18
16.75
16.07
Profit Before Tax
89.57
63.81
44.37
-5.28
84.34
56.81
42.26
Tax
22.54
16.50
11.23
-1.10
25.86
18.05
15.73
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
67.03
47.32
33.15
-4.18
58.48
38.75
26.53
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
67.03
47.32
33.15
-4.18
58.48
38.75
26.53
Share in Profit of Associates
2.24
1.50
-0.60
-6.83
-2.93
0.64
-1.26
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
69.27
48.82
32.55
-11.02
55.55
39.39
25.27
Equity Capital
9.37
8.47
8.47
8.47
8.47
8.47
8.47
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Diluted Earnings per share
2.59
2.15
1.36
0.44
1.07
2.53
0.9
Operating Profit Margin (Excl OI)
20.25%
18.37%
17.91%
8.39%
25.77%
20.42%
20.81%
Gross Profit Margin
18.39%
16.75%
14.67%
5.06%
23.65%
18.77%
18.49%
PAT Margin
10.33%
8.85%
7.15%
-1.12%
12.74%
9.89%
8.41%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Nine Monthly Analysis Highlights
stock-summary

Net Sales

YoY Growth in nine months ended Dec 2025 is 21.40% vs 15.34% in Dec 2024

stock-summary

Consolidate Net Profit

YoY Growth in nine months ended Dec 2025 is 41.89% vs 49.98% in Dec 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in nine months ended Dec 2025 is 33.80% vs 18.30% in Dec 2024

stock-summary

Interest

YoY Growth in nine months ended Dec 2025 is 32.15% vs -24.50% in Dec 2024

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in nine months ended Dec 2025 has improved from Dec 2024

Compare Nine Monthly Results Of SMS Pharma. With
Markets Mojo
Figures in Cr
Consolidate Nine Monthly Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
Net Sales
648.93
1,626.73
-977.80
-60.11%
Other Operating Income
0.00
0.00
0.00
Total Operating income
648.93
1,626.73
-977.80
-60.11%
Raw Material Cost
392.41
584.80
-192.39
-32.90%
Purchase of Finished goods
0.00
139.70
-139.70
-100.00%
(Increase) / Decrease In Stocks
-27.85
28.03
-55.88
-199.36%
Employee Cost
58.49
306.82
-248.33
-80.94%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
67.26
0.00
67.26
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
27.24
433.93
-406.69
-93.72%
Total Expenditure (Excl Depreciation)
517.55
1,493.28
-975.73
-65.34%
Operating Profit (PBDIT) excl Other Income
131.38
133.45
-2.07
-1.55%
Other Income
5.78
39.59
-33.81
-85.40%
Operating Profit (PBDIT)
137.16
173.04
-35.88
-20.74%
Interest
17.80
22.20
-4.40
-19.82%
Exceptional Items
0.00
217.26
-217.26
-100.00%
Gross Profit (PBDT)
119.36
368.10
-248.74
-67.57%
Depreciation
29.79
94.51
-64.72
-68.48%
Profit Before Tax
89.57
273.59
-184.02
-67.26%
Tax
22.54
31.66
-9.12
-28.81%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
67.03
241.93
-174.90
-72.29%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
67.03
241.93
-174.90
-72.29%
Share in Profit of Associates
2.24
0.00
2.24
Minority Interest
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
69.27
241.93
-172.66
-71.37%
Equity Capital
9.37
14.08
-4.71
-33.45%
Face Value
1.00
2.00
0.00
Reserves
0.00
0.00
0.00
Gross Profit Margin
18.39%
22.63%
0.00
-4.24%
PAT Margin
10.33%
14.87%
0.00
-4.54%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Nine Monthly - Net Sales
Net Sales 648.93 Cr
in Dec 2025

Figures in Cr
stock-summary

YoY Growth in nine months ended Dec 2025 is 21.40% vs 15.34% in Dec 2024

Nine Monthly - Consolidate Net Profit
Consolidate Net Profit 69.27 Cr
in Dec 2025

Figures in Cr
stock-summary

YoY Growth in nine months ended Dec 2025 is 41.89% vs 49.98% in Dec 2024

Nine Monthly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 131.38 Cr
in Dec 2025

Figures in Cr
stock-summary

YoY Growth in nine months ended Dec 2025 is 33.80% vs 18.30% in Dec 2024

Nine Monthly - Interest
Interest 17.80 Cr
in Dec 2025

Figures in Cr
stock-summary

YoY Growth in nine months ended Dec 2025 is 32.15% vs -24.50% in Dec 2024

Nine Monthly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 20.25%
in Dec 2025

Figures in %
stock-summary

YoY Growth in nine months ended Dec 2025 has improved from Dec 2024